RPL26B Antibody

What is RPL26 and why is it significant in cellular research?

RPL26 (Ribosomal Protein L26) is a crucial component of the 60S ribosomal subunit involved in protein synthesis. Its significance extends beyond ribosomal structure, as it plays key roles in p53 mRNA translation and cellular stress responses. In research, RPL26 serves as an important marker for studying ribosome biogenesis, protein synthesis regulation, and quality control mechanisms. Studies have demonstrated that RPL26 can be targeted for ubiquitination and degradation by UBE2S, highlighting its involvement in protein degradation pathways . Understanding RPL26 function provides insights into fundamental cellular processes including translation control, ribosomal assembly, and protein homeostasis mechanisms.

Selection of an appropriate RPL26 antibody should be guided by:

• Epitope recognition: Different antibodies target specific regions of RPL26. For example, some antibodies recognize the N-terminal region (AA 1-95), while others target C-terminal or middle regions . Consider which domain is accessible in your experimental conditions and whether post-translational modifications might mask your epitope of interest.

• Species reactivity: Verify cross-reactivity with your model organism. Some RPL26 antibodies show high sequence identity across species: 100% for human, mouse, rat, bovine and monkey, 97% for Xenopus, and 95% for zebrafish .

• Antibody format: Available as unconjugated or conjugated (HRP, FITC, biotin) for different applications . Conjugated versions may offer advantages for direct detection without secondary antibodies.

• Validation data: Review published literature and manufacturer validation data to confirm the antibody's performance in your specific application . The Proteintech RPL26 antibody (17619-1-AP), for instance, has been cited in multiple publications for Western blot, immunohistochemistry, and co-immunoprecipitation applications .

When possible, conduct preliminary validation experiments with positive controls to confirm specificity before proceeding with your critical experiments.

What is the optimal protocol for Co-IP experiments using RPL26 antibodies?

The optimal protocol for Co-IP using RPL26 antibodies involves several critical steps:

• Cell lysis and pre-clearing:

  • Extract total protein using IP lysis buffer (e.g., Beyotime buffer)

  • Pre-purify with 30 μL protein A/G magnetic beads at 4°C

  • This reduces non-specific binding

• Antibody binding to beads:

  • Mix 50 μL magnetic beads with 2-3 μg anti-RPL26 antibody (e.g., ABclonal A16680)

  • Include control IgG antibody (e.g., Santa Cruz SC-2025) in parallel reactions

  • Pre-incubate at 4°C for 4 hours

• Immunoprecipitation:

  • Incubate antibody-bead complex with total protein overnight at 4°C

  • Maintain constant gentle rotation

• Washing and elution:

  • Wash beads three times with washing buffer for 15 minutes each

  • Resuspend in 50 μL lysis buffer containing 1× SDS loading buffer

  • Denature proteins at 100°C for 10 minutes

• Western blot analysis:

  • Probe for interaction partners (e.g., UBE2S when studying ubiquitination pathways)

This protocol has been successfully used to demonstrate interactions between RPL26 and UBE2S, confirming RPL26's role in ubiquitination pathways . For detecting ubiquitinated RPL26, use anti-Ub antibody (e.g., Proteintech 10201-2-AP, 1:1000) for Western blotting after immunoprecipitation .

How can I optimize Western blotting for detecting RPL26 in different cellular fractions?

Optimizing Western blotting for RPL26 detection across cellular fractions requires attention to several parameters:

• Sample preparation by cellular compartment:

  • For nucleolar fractions (where unassembled RPL26 often accumulates), use specialized nuclear extraction buffers

  • For ribosomal fractions, consider sucrose gradient fractionation to separate free RPL26 from ribosome-incorporated protein

• Gel selection and running conditions:

  • Use 12-15% polyacrylamide gels for optimal resolution of RPL26 (~17 kDa)

  • Consider gradient gels (4-20%) when examining both free RPL26 and its higher molecular weight ubiquitinated forms

• Antibody selection and dilution:

  • Primary antibody: 1:500-1:1000 dilution (e.g., Proteintech 17619-1-AP)

  • Extended incubation at 4°C overnight often improves signal quality

• Detection considerations:

  • Enhanced chemiluminescence detection works well for standard applications

  • For detecting low abundance forms, consider fluorescent secondary antibodies for better quantification

• Controls and troubleshooting:

  • Include subcellular fraction markers to confirm proper fractionation

  • Be aware that RPL26 in low-MW fractions may show faster migration on SDS-PAGE compared to assembled RPL26, suggesting possible processing

Research has shown that ubiquitinated RPL26 species are exclusively found in unassembled fractions rather than in 40S/60S/80S ribosomes or polysomes , making fractionation an important technique for studying RPL26 modification states.

What approaches can detect ubiquitinated forms of RPL26?

Detecting ubiquitinated forms of RPL26 requires specialized techniques:

• UBA resin enrichment:

  • Affinity-purify ubiquitin-conjugated proteins using ubiquitin-binding UBA domain resin

  • Immunoblot with anti-RPL26 antibody to detect high-molecular weight conjugated forms

  • This approach has successfully demonstrated that high-MW forms of RPL26 accumulate in the presence of proteasome inhibitors

• Denaturing immunoprecipitation:

  • Immunoprecipitate RPL26 under denaturing conditions to dissociate interacting proteins

  • Probe with anti-ubiquitin antibody to confirm ubiquitination

  • This method prevents co-purification of other ubiquitinated proteins that might associate with RPL26

• Deubiquitinase treatment:

  • Digest UBA resin eluates with deubiquitinating enzyme (e.g., Usp2)

  • Monitor time-dependent loss of high-MW species and increase in unmodified RPL26

  • This confirms that the high-MW species are indeed ubiquitin conjugates

• Sucrose gradient fractionation with UBA pull-down:

  • Fractionate cell lysates on sucrose gradients to separate unassembled, 40S/60S/80S, and polysome fractions

  • Apply UBA resin to each fraction to capture ubiquitinated proteins

  • Research has shown that ubiquitin-conjugated species of RPL26 are exclusively found in the unassembled fraction

• Proteasome inhibitor treatment:

  • Treat cells with proteasome inhibitors like bortezomib (50 μM) to cause accumulation of ubiquitinated forms

  • This approach increases detection sensitivity for these normally transient species

How can RPL26 antibodies be used to study ribosome assembly and quality control mechanisms?

RPL26 antibodies serve as valuable tools for investigating ribosome assembly and quality control through several sophisticated approaches:

• Sucrose gradient ribosome profiling:

  • Fractionate cell lysates on 7-47% sucrose gradients

  • Use RPL26 antibodies to track distribution between unassembled, 40S/60S/80S, and polysome fractions

  • This allows quantification of assembly efficiency and detection of assembly defects

  • Research has shown that unassembled excess RPL26 accumulates in low-MW fractions and is targeted for degradation

• Pulse-chase immunoprecipitation:

  • Metabolically label newly synthesized proteins with radioactive amino acids

  • Immunoprecipitate RPL26 at various chase timepoints

  • Quantify incorporation into ribosomes versus degradation of unassembled forms

  • This approach can measure kinetics of assembly versus degradation

• Proximity labeling with RPL26 antibodies:

  • Couple RPL26 antibodies with proximity labeling enzymes (BioID, APEX)

  • Identify proteins in close proximity to RPL26 during assembly or degradation

  • This can reveal novel quality control factors involved in RPL26 processing

• Inhibitor studies:

  • Treat cells with proteasome inhibitors (bortezomib) or autophagy inhibitors

  • Track accumulation of unassembled RPL26 using fractionation and immunoblotting

  • Research has demonstrated that excess ribosomal proteins, including RPL26, are degraded by the ubiquitin-proteasome system rather than autophagy

• Genetic perturbation analysis:

  • Examine RPL26 fate in cells with mutations in various degradation pathways

  • For example, studies in pre9Δ mutants (lacking the nonessential α3 subunit of the 20S proteasome) showed accumulation of high-MW forms of RPL26, confirming proteasomal degradation

These approaches have revealed that ubiquitination and degradation pathways are exquisitely specific for unassembled forms of RPL26, providing quality control to prevent accumulation of potentially toxic unincorporated ribosomal proteins .

What are the challenges in distinguishing between normal and ubiquitinated RPL26 in complex samples?

Distinguishing between normal and ubiquitinated RPL26 in complex samples presents several technical challenges:

• Multiple ubiquitination states:

  • RPL26 can be mono-ubiquitinated or poly-ubiquitinated with various chain topologies

  • This creates a heterogeneous population of modified proteins appearing as a ladder or smear on Western blots

  • Solution: Use chain-specific ubiquitin antibodies (K48-specific, K63-specific) to characterize modification types

• Low abundance of ubiquitinated forms:

  • Ubiquitinated RPL26 is rapidly degraded by the proteasome under normal conditions

  • These forms represent a small fraction of total RPL26

  • Solution: Use proteasome inhibitors like bortezomib (50 μM) to stabilize ubiquitinated species

• Interference from interacting proteins:

  • RPL26 exists in complexes with numerous proteins in cellular lysates

  • Other ubiquitinated proteins may co-purify with RPL26

  • Solution: Perform immunoprecipitation under denaturing conditions to dissociate protein-protein interactions before analysis

• Similarity to other ribosomal proteins:

  • RPL26 shares sequence homology with other ribosomal proteins

  • Antibody cross-reactivity can complicate interpretation

  • Solution: Validate antibody specificity using knockout/knockdown controls; the high MW ubiquitinated forms should disappear in RPL26 knockout samples

• Subcellular compartmentalization:

  • Unassembled and ubiquitinated RPL26 shows distinct localization compared to ribosome-incorporated RPL26

  • Solution: Perform subcellular fractionation before analysis; research has shown ubiquitinated RPL26 is exclusively in unassembled fractions not incorporated into ribosomes

Research has demonstrated that combining approaches such as sucrose gradient fractionation, UBA resin enrichment, and denaturing immunoprecipitation can effectively distinguish and characterize ubiquitinated RPL26 species .

How can RPL26 antibodies be used in studies of the UBE2S-mediated ubiquitination pathway?

RPL26 antibodies are instrumental in investigating the UBE2S-mediated ubiquitination pathway through several sophisticated approaches:

• Co-immunoprecipitation to confirm direct interaction:

  • Use anti-RPL26 antibody (e.g., ABclonal A16680) to immunoprecipitate RPL26

  • Probe for UBE2S in the immunoprecipitate

  • Alternatively, immunoprecipitate with anti-UBE2S antibody (e.g., Proteintech 14115-1-AP) and detect RPL26

  • This approach has confirmed direct interaction between RPL26 and UBE2S

• In vitro ubiquitination assays:

  • Immunoprecipitate RPL26 for use as substrate

  • Incubate with purified ubiquitination components: E1 (Ube1), E2 (UbcH5a), His6-ubiquitin, and ATP

  • Detect ubiquitinated RPL26 using anti-ubiquitin antibodies

  • This approach demonstrates direct ubiquitination of RPL26 by specific E2/E3 complexes

• Ubiquitination site mapping:

  • Immunoprecipitate RPL26 after UBE2S-mediated ubiquitination

  • Analyze by mass spectrometry to identify specific lysine residues modified by ubiquitin

  • Create lysine-to-arginine mutants of RPL26 to confirm functional significance of specific sites

• Degradation kinetics analysis:

  • Perform cycloheximide chase experiments in cells with normal or depleted UBE2S

  • Immunoprecipitate RPL26 at various timepoints and quantify by immunoblotting

  • This approach can determine how UBE2S affects RPL26 stability and turnover

• Cellular localization studies:

  • Use RPL26 antibodies for immunofluorescence (1:50-1:500 dilution)

  • Co-stain for UBE2S and ubiquitin

  • Research has shown that unassembled RPL26 accumulates in the nucleus and nucleolus where it can be targeted by ubiquitin ligases

These approaches have revealed that UBE2S targets RPL26 for ubiquitination and degradation, highlighting an important regulatory mechanism for controlling ribosomal protein levels and potentially influencing translation dynamics .

What are common issues when using RPL26 antibodies and how can they be resolved?

Common issues with RPL26 antibodies and their solutions include:

• High background in Western blots:

  • Problem: Non-specific binding to other ribosomal proteins

  • Solution: Increase blocking time/concentration (5% BSA instead of milk), optimize antibody dilution (try 1:1000 instead of 1:500), consider more stringent washing conditions with higher salt concentration

  • Validated approach: The Proteintech RPL26 antibody (17619-1-AP) has been optimized for WB at 1:500-1:1000 dilution

• Weak or undetectable signal:

  • Problem: Low abundance of free RPL26 (most is ribosome-incorporated)

  • Solution: Enrich for non-ribosomal fractions using sucrose gradient fractionation, increase antibody incubation time to overnight at 4°C, consider proteasome inhibitor treatment to increase unassembled RPL26 levels

  • Research data: Bortezomib treatment (50 μM) significantly increases detection of unassembled RPL26

• Multiple bands or unexpected molecular weights:

  • Problem: Detection of processed forms or ubiquitinated species

  • Solution: Use higher percentage gels (15%) for better resolution, compare with fractionation data to identify which forms correspond to which cellular pool

  • Research finding: RPL26 in low-MW fractions may show faster migration on SDS-PAGE compared to assembled RPL26, suggesting processing

• Poor co-immunoprecipitation efficiency:

  • Problem: Limited accessibility of epitopes in protein complexes

  • Solution: Try different RPL26 antibodies targeting different epitopes, optimize lysis conditions to preserve interactions while ensuring efficient extraction

  • Validated protocol: Using 50 μL magnetic beads with 2-3 μg anti-RPL26 antibody with overnight incubation at 4°C

• Cross-reactivity concerns:

  • Problem: RPL26 shares sequence homology with other ribosomal proteins

  • Solution: Include RPL26 knockdown/knockout controls, validate using recombinant RPL26 protein, consider using antibodies raised against unique regions

  • Specificity data: Antibodies like ABIN1500743 are generated against specific amino acid regions (AA 1-95) to improve specificity

How should experimental protocols be modified when studying RPL26 in different model organisms?

When adapting RPL26 antibody protocols across model organisms, consider these modifications:

• Species-specific antibody selection:

  • Human/mouse/rat/bovine/monkey: Most antibodies show 100% cross-reactivity due to sequence conservation

  • Xenopus: 97% sequence identity may require higher antibody concentrations (1.2-1.5× standard dilution)

  • Zebrafish: 95% sequence identity; validate antibody specificity with recombinant protein controls

  • Consider species-reactivity data when selecting antibodies; for example, ABIN1500743 has predicted reactivity with multiple species based on BLAST analysis

• Lysis buffer optimization:

  • Yeast models: More aggressive lysis conditions with glass bead disruption in buffer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% NP-40

  • Mammalian cells: Standard RIPA or NP-40 buffers are typically sufficient

  • Tissue samples: May require mechanical homogenization and stronger detergents

• Immunoprecipitation adjustments:

  • Increase antibody amount (~25-50%) when using in non-human models

  • Extend incubation times for cross-species applications

  • Include species-specific IgG controls for each new organism

• Western blotting modifications:

  • Adjust transfer conditions for different tissue types (longer transfer times for denser tissues)

  • Optimize blocking solutions to minimize background (species-specific serum may help)

  • Validate with recombinant RPL26 from the species of interest

• Control selection:

  • For yeast: Use tom1 mutants which accumulate unassembled Rpl26

  • For mammalian cells: siRNA knockdown of RPL26 provides specificity control

  • Genetic models: Consider RPL26 conditional knockout animals where available

Research with yeast models has provided valuable insights into RPL26 regulation, showing that unassembled Rpl26a is targeted by Tom1 for ubiquitination, with similar mechanisms likely conserved in higher eukaryotes .

What considerations are important when using RPL26 antibodies to study ribosomal stress responses?

When investigating ribosomal stress responses with RPL26 antibodies, consider these important methodological aspects:

• Timing of stress response analysis:

  • Acute responses: Examine 1-4 hours post-stressor application

  • Chronic responses: Monitor 12-48 hours for adaptive changes

  • Pulse-chase approaches can distinguish between effects on new synthesis versus degradation of existing RPL26

• Stress condition optimization:

  • Ribosomal stress can be induced with nucleolar stressors (actinomycin D at low doses)

  • Proteasome inhibitors (bortezomib at 50 μM) reveal degradation-dependent regulation

  • Nutrient deprivation triggers physiologically relevant ribosomal stress

• Subcellular localization analysis:

  • Under stress, RPL26 often shows altered nucleolar/nuclear distribution

  • Immunofluorescence with RPL26 antibodies (1:50-1:500 dilution) can track these changes

  • Research has shown unassembled RPL26 accumulates in the nucleus and nucleolus under certain stress conditions

• Interaction dynamics assessment:

  • RPL26 interactions with p53 mRNA and MDM2 change under stress

  • Co-immunoprecipitation with RPL26 antibodies can track these altered interactions

  • Consider native versus cross-linked immunoprecipitation to preserve transient interactions

• Multi-parameter analysis:

  • Combine RPL26 antibody staining with markers of cell cycle, apoptosis, or autophagy

  • This provides context for understanding how RPL26 changes relate to cellular outcomes

  • Include markers for nucleolar stress (NPM1 localization) and translation status (phospho-S6)

• Controls and validation:

  • Include both positive controls (known ribosomal stressors) and negative controls

  • Validate findings with orthogonal approaches (e.g., RPL26-GFP fusion proteins)

  • Consider genetic approaches (RPL26 knockdown/overexpression) to confirm antibody-based findings

Research has demonstrated that unassembled ribosomal proteins accumulated during stress are specifically recognized by quality control systems, with RPL26 serving as an excellent model for studying these processes .

How are RPL26 antibodies being used to investigate extraribosomal functions?

RPL26 antibodies are enabling investigation of several emerging extraribosomal functions through targeted methodologies:

• p53 regulatory pathway analysis:

  • RPL26 binds p53 mRNA and enhances its translation

  • Co-immunoprecipitation with RPL26 antibodies followed by RNA extraction can identify bound mRNAs

  • Western blotting can detect RPL26-p53 protein interactions in stress conditions

  • This approach has revealed how RPL26 contributes to cellular stress responses beyond its ribosomal role

• Cell cycle regulation studies:

  • Synchronize cells at different cell cycle phases

  • Immunoprecipitate RPL26 and identify phase-specific interaction partners

  • Combine with flow cytometry to correlate RPL26 status with cell cycle progression

  • These approaches can elucidate how RPL26 contributes to cell cycle control

• DNA damage response investigation:

  • Induce DNA damage with agents like etoposide or UV radiation

  • Track RPL26 localization changes using immunofluorescence (1:50-1:500 dilution)

  • Immunoprecipitate RPL26 to identify damage-specific interactions

  • This can reveal mechanisms connecting ribosome biogenesis to genome stability

• Investigation of RPL26 in specialized cellular compartments:

  • Perform subcellular fractionation to isolate mitochondria, nucleoli, and other compartments

  • Use RPL26 antibodies to detect non-ribosomal pools

  • This approach can identify novel functions in unexpected cellular locations

• Stress granule association:

  • Induce stress granule formation with arsenite or heat shock

  • Co-stain for RPL26 and stress granule markers

  • Immunoprecipitate RPL26 to identify stress granule-specific interactions

  • This can reveal roles in translational regulation during stress

These diverse approaches have expanded our understanding of RPL26 beyond its canonical ribosomal function, positioning it as a multifunctional protein involved in various cellular processes.

What are emerging applications of RPL26 antibodies in cancer research?

RPL26 antibodies are finding novel applications in cancer research through several methodological approaches:

• Cancer tissue microarray analysis:

  • Immunohistochemistry with RPL26 antibodies across multiple tumor types

  • Correlation with clinical outcomes and pathological features

  • This approach can identify cancer types where RPL26 has prognostic significance

  • Research using RPL26 antibodies has demonstrated altered expression across various cancer types

• p53 pathway dysregulation studies:

  • Compare RPL26-p53 interactions between normal and cancer cells

  • Immunoprecipitate RPL26 to assess binding to p53 mRNA and protein

  • This can reveal how cancer cells subvert RPL26's p53-regulatory function

  • RPL26 has been shown to interact with p53 and p73, key tumor suppressors

• Cancer stem cell identification:

  • Co-staining of RPL26 with cancer stem cell markers

  • Flow cytometry sorting based on RPL26 levels

  • This approach can identify potential relationships between ribosome composition and stemness

  • RPL26 has been studied alongside stemness markers like ALDH1A1 and Nanog

• Therapeutic response prediction:

  • Analyze RPL26 expression and modification patterns before/after treatment

  • Correlate with therapeutic sensitivity

  • This can identify RPL26 as a potential biomarker for treatment selection

  • Proteasome inhibitors like bortezomib affect RPL26 degradation, suggesting potential therapeutic implications

• RNA-protein interaction mapping in cancer contexts:

  • CLIP-seq (cross-linking immunoprecipitation) with RPL26 antibodies

  • Compare RNA binding profiles between normal and malignant cells

  • This can reveal cancer-specific RPL26-RNA interactions

  • The cancer-specific RNA targets of RPL26 may represent novel therapeutic opportunities

These applications highlight RPL26's emerging role as both a cancer biomarker and a mechanistic player in cancer development and treatment response.

How can researchers combine RPL26 antibodies with emerging technologies for more comprehensive analyses?

Researchers can leverage RPL26 antibodies with cutting-edge technologies through the following methodological approaches:

• Proximity labeling proteomics:

  • Conjugate RPL26 antibodies to proximity labeling enzymes (BioID, APEX)

  • Identify proteins in close proximity to RPL26 in different cellular contexts

  • This approach can map the dynamic RPL26 "interactome" with spatial resolution

  • The method reveals context-specific interaction partners beyond what traditional co-IP detects

• Single-cell analysis:

  • Combine RPL26 antibodies with single-cell Western or CyTOF technologies

  • Correlate RPL26 status with other cellular parameters at single-cell resolution

  • This reveals cell-to-cell heterogeneity in RPL26 expression and modification

  • Single-cell approaches can identify rare cell subpopulations with unique RPL26 characteristics

• Live-cell imaging with nanobodies:

  • Develop anti-RPL26 nanobodies conjugated to fluorescent proteins

  • Track RPL26 dynamics in living cells in real-time

  • This approach reveals temporal aspects of RPL26 trafficking and interactions

  • Real-time imaging provides insights into RPL26 behavior during cellular processes

• CRISPR-Cas9 screening combined with RPL26 antibody readouts:

  • Perform genome-wide CRISPR screens for genes affecting RPL26 levels or modification

  • Use RPL26 antibodies for high-throughput immunofluorescence or flow cytometry readouts

  • This identifies novel regulators of RPL26 biology

  • Genetic screens can uncover unexpected pathways influencing RPL26 function

• Spatial proteomics:

  • Apply multiplexed immunofluorescence with RPL26 antibodies

  • Map RPL26 distribution across tissue architecture with subcellular resolution

  • This reveals tissue-specific RPL26 expression patterns and potential functions

  • Spatial context provides insights into RPL26 roles in complex tissues

These integrated approaches expand the utility of RPL26 antibodies beyond traditional applications, enabling systems-level understanding of RPL26 biology in normal and disease contexts.